Should I Buy IART? IART 2026 Analysis

Should You Buy Integra Lifesciences Holdings Corp (IART) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

11.090

1 Day change

1.93%

52 Week Range

27.130

Analysis Updated At

2026/01/29

Not a good buy right now for a beginner long-term investor. Despite being deeply oversold (RSI ~16) and near support (~$10.58–$11.09) which can spark short bounces, the primary driver is negative, event-driven risk (FDA alert + full MediHoney recall with reported serious injuries). With the trend still firmly bearish (downward moving averages and weakening MACD) and Wall Street ratings skewing to Hold/Underweight/Sell with lowered targets, the risk/reward is unfavorable for an impatient investor seeking a long-term entry today. If you already own it, this is a sell/trim situation rather than adding.

Technical Analysis

Trend and momentum are bearish: - Moving averages: Bearish stack (SMA_200 > SMA_20 > SMA_5) confirms a sustained downtrend. - MACD: Histogram -0.184 and negatively expanding = downside momentum is still strengthening, not stabilizing. - RSI(6): 16.0 = extremely oversold, which can produce short-term mean-reversion bounces, but oversold alone is not a trend reversal signal. - Key levels: Price $10.88 is below S1 ($11.09) and sitting just above S2 ($10.58). A clean break below ~$10.58 would suggest further downside; upside recovery levels to watch are the pivot ~$11.93 then ~$12.76. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning looks call-heavy but conviction is limited: - Open interest put/call ratio: 0.17 (very low) = more call OI than puts, typically a bullish/less-hedged stance. - Volume put/call ratio: 0.0 = only call volume showed today, but total volume is tiny (9 contracts), so sentiment inference is weak. - Volatility: Very high (IV ~82% vs historical vol ~91%); IV rank ~26 and percentile ~45 suggests elevated but not at extremes. This aligns with uncertainty around negative headlines rather than clean bullish positioning.

Technical Summary

Sell

Buy

Positive Catalysts

- Deeply oversold technical condition (RSI ~16) can trigger sharp relief rallies if bad news gets digested.
- Next earnings: QDEC 2025 reported 2026-02-23 (pre-market) could reset the narrative if management shows containment of the recall impact and improving execution.
- Pattern-based stats provided suggest a rebound bias (model indicates 60% chance of gains over 1 day/1 week/1 month), though this is secondary to the current event risk.

Neutral/Negative Catalysts

- FDA alert on packaging defects + recall of all MediHoney wound/burn products and specific CVS Wound Gel lots.
- Reported serious injuries (11 linked to MediHoney; 3 associated with CVS Wound Gel) increases litigation, remediation, reputation, and revenue-risk overhang.
- Technical trend remains decisively bearish (bearish MA stack and worsening MACD), implying the market is still pricing in negative developments.
- No supportive “smart money” signal: hedge funds and insiders are neutral recently (no notable accumulation signal).

Financial Performance

Latest reported quarter: 2025/Q3. - Revenue: $402.06M, up 5.57% YoY (top-line growth is positive). - Net income: -$5.40M (loss), down 49.47% YoY (profitability deteriorated). - EPS: -$0.07, down 50.0% YoY (earnings trend negative). - Gross margin: 56.24%, slightly down (~-0.05% YoY), showing no meaningful margin expansion. Overall: growth exists, but profitability and EPS momentum weakened entering a period now complicated by a product recall headline risk.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent Wall Street trend is negative to cautious with modestly reduced targets: - Truist (2025-11-03): Hold; PT cut to $13 from $15; cited surprise Q3 revenue miss after multiple outlook rebases. - JPMorgan (2025-10-31): Underweight; PT raised to $13 from $12 (still bearish stance despite slightly higher target). - Citi (2025-10-31): Sell; PT cut to $11 from $12. Pros (bull case): targets cluster around $11–$13 vs price ~$10.88 suggests limited upside to consensus targets if issues stabilize. Cons (bear case): rating mix is Hold/Underweight/Sell with commentary focused on execution misses; combined with the FDA/recall news flow, the fundamental/credibility overhang remains high. Influential/political trading check: No recent congress trading data available (and no noted politician activity in the provided data).

6 Analyst Rating

Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 12.33 USD with a low forecast of 10 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

4 Sell

Moderate Sell

Current: 10.880

Low

Averages

12.33

High

Current: 10.880

Low

Averages

12.33

High

Truist

Hold

downgrade

$15 -> $13

AI Analysis

2025-11-03

Reason

Truist

Price Target

$15 -> $13

AI Analysis

2025-11-03

downgrade

Hold

Reason

Truist lowered the firm's price target on Integra LifeSciences to $13 from $15 and keeps a Hold rating on the shares. The firm notes it was surprised to see a Q3 revenue miss following multiple rebased outlooks, including last quarter. The intra-quarter issues impacted the business and more than overshadowed progress made on profitability and free cash flow, the analyst tells investors in a research note.

JPMorgan

Robbie Marcus

Underweight

maintain

$12 -> $13

2025-10-31

Reason

JPMorgan

Robbie Marcus

Price Target

$12 -> $13

2025-10-31

maintain

Underweight

Reason

JPMorgan analyst Robbie Marcus raised the firm's price target on Integra LifeSciences to $13 from $12 and keeps an Underweight rating on the shares. The firm updated the company's model.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IART

Unlock Now

IART Should I Buy

IART Should I Buy

Should You Buy Integra Lifesciences Holdings Corp (IART) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch